explore -WSS

explore

author：Wikipedia 2025-10-03 00:40:04 - browse：5

Adam's take main illustration — Molly Ferguson/STAT

Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.

Bluebird and the case for gene therapy profits

Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? I’m not sure anyone knows yet for sure, but pay attention to Bluebird Bio over the next year for some clues.

Bluebird is unique among the biotech and pharma companies selling gene therapies (or CRISPR-based medicines) today because it has no other marketed products. With the recent approval of Lyfgenia for sickle cell disease (cost: $3.1 million), Bluebird sells three gene therapies. The other products are Zynteglo for beta thalassemia ($2.8 million) and Skysona for cerebral adrenoleukodystrophy ($3 million). It’s a pure-play commercial gene therapy business. It’s not even trying to develop additional gene therapies currently. R&D expenses are tied to gathering long-term data on its existing products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Congress might make insulin pumps more accessible to the blind

explore

WSS

Tome Biosciences co

Public health communication lessons from Covid

Marc Tessier

Timeline: Special counsel's probe into Trump's handling of classified documents

Eli Lilly reports tirzepatide MASH success during Q4 earnings

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

hotspot

explore

Bluebird and the case for gene therapy profits

knowledge

ChatGPT in medicine: STAT answers readers' burning questions

Resistance to opioid

Malaria cases in Florida and Texas: Here’s what you need to know

Interest rates are at a 22

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Here’s what’s in the FDA plan to include pregnant women in clinical trials

The high cost of giving birth even with insurance

Alexander Hamilton and the argument for universal insurance

23andMe had bad news about my health. I wish a person had delivered it

ACIP vaccine advisory panel sees its vacancies filled

hotspot

Biden to sign 'historic' executive order on how US military handles sexual assault cases

Doctors on social media are being harassed and cyberbullied

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Congress considering partial increase for doctor pay in Medicare

The mammogram wars are not over

Latigo launches with $135 million for Vertex

hotspot

explore

leisure time

hotspot